Septerna, Inc. has appointed Gil M. Labrucherie as Chief Financial Officer, principal financial officer, and principal accounting officer, effective January 6, 2025. Labrucherie, with over 25 years in senior leadership in the biotech sector, previously worked at Acelyrin, Inc. and Nektar Therapeutics, and has been a trustee of the Bloom Trust and served on boards including Rezolute, Inc. He also practiced law at Wilson Sonsini Goodrich & Rosati, P.C., is a CFA charterholder, and a member of the State Bar of California. His compensation includes a $485,000 annual base salary, 40% target bonus, and executive severance benefits.
Correspondingly, Ran Xiao, who served as the Interim Chief Financial Officer, will resign from this role effective January 6, 2025, but will continue as Vice President of Finance and Business Operations. Alongside this transition, Septerna has issued a press release announcing Labrucherie's appointment.
Names: - Septerna, Inc. - Gil M. Labrucherie - Acelyrin, Inc. - Nektar Therapeutics - Bloom Trust - Rezolute, Inc. - Wilson Sonsini Goodrich & Rosati, P.C. - Valinor Pharma LLC - Grünenthal - Ran Xiao - Jeffrey Finer, M.D., Ph.D.